determining the most suitable consolidation therapies for aml by defining patient risk group
Published 1 year ago • 274 plays • Length 5:05Download video MP4
Download video MP3
Similar videos
-
3:14
determining the optimal frontline treatment of aml
-
3:33
mrd conversion rate with consolidation chemotherapy in aml
-
2:43
diagnostic tools for aml
-
2:45
continuity of care for patients with hematological predispositions to aml
-
19:31
utilizing mrd for aml in the clinical setting
-
9:38
pathology-acute myeloid leukemia | aml made easy | clinical features and diagnosis #acuteleukemias
-
8:08
advances and challenges in aml treatment
-
4:53
what is consolidation therapy? #aml
-
2:40
the role of consolidation therapy in mm and updates from the emn02 trial
-
2:11
selecting aml patients for intensive treatment
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
2:11
beat aml master trial: novel precision medicine approach in aml
-
3:24
molecular profiling to determine treatment for all and aml
-
3:40
how the aml treatment landscape has evolved with the use of novel combination therapies
-
1:42
novel treatment combinations in aml: what’s to come?
-
1:21
intensive therapy of older aml
-
1:39
optimizing chemotherapy in aml
-
1:10
novel methods to assess the effectiveness of chemotherapy in aml patients: mrd
-
1:35
maintenance & consolidation strategies for all and their impact on qol
-
0:51
key unmet needs in the treatment of immune-mediated ttp
-
5:01
novel classification system to improve post-transplant aml prognosis
-
2:14
update on the aml treatment landscape